Chaewon Lee

Papers

1

Total Citations

16

H-Index

1

About

Chaewon Lee is a translational pain researcher whose work bridges molecular pharmacology and clinical analgesia, with a focus on postoperative pain management. Her most cited study investigates VVZ-149, a novel dual-action analgesic that inhibits both the glycine transporter type 2 and the serotonin 5-HT2A receptor. In a randomized, double-blind, proof-of-concept trial involving patients undergoing laparoscopic and robotic-laparoscopic gastrectomy, Lee demonstrated that VVZ-149 significantly reduces the affective—or emotional—component of pain, a dimension often undertreated by conventional opioids. This work, cited 16 times, highlights her contribution to developing non-opioid alternatives that target both sensory and affective pain pathways. Lee’s research is notable for its direct clinical translation, addressing a critical need in perioperative care by offering a potential solution to opioid-related side effects and dependence. Her findings have implications for enhanced recovery after surgery (ERAS) protocols, positioning her as an emerging voice in mechanism-based pain therapeutics. For students and researchers, Lee’s work exemplifies how preclinical insights into neurotransmitter systems can be rigorously tested in human trials to reshape postoperative pain management.

Research Focus

Key Achievements

1
H-Index
1
Papers
16
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
Role of VVZ-149, a Novel Analgesic Molecule, in the Affective Component of Pain: Results from an Exploratory Proof-of-Concept Study of Postoperative Pain following Laparoscopic and Robotic-Laparoscopic Gastrectomy
16 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 6

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago